Luteal Phase Support During Frozen Embryo Transfer Cycle

Royan Institute

Status and phase: Completed; Phase 3

Conditions: Frozen Embryo Transfer; Infertility, Female

Treatments: Drug: Strogen

Study type: Interventional

Funder types: Other

Identifiers

NCT04013438

Royan, Female Infertility,LPS

Details and patient eligibility

About

We aimed to decrease quantity of exogenous estrogen and evaluated the success rate of ongoing pregnancy in women undergone artificial FET who have a surplus embryos at previous fertility treatment cycles.

In this study, endometrial prepared with standard long GnRH protocol and for luteal phase support patients received 6 mg oral E2 and intramuscularly P 100 mg/d and embryos on day 2-3 were transferred. Control group continued E2 until 12 week of pregnancy, while for cases after identify gestational sac with heart beat (the 6 week of pregnancy) by vaginal ultrasonography, E2 will discontinued.

Full description

Approval Status: Confirmed Approval reference Number: IR.ACECR.ROYAN.REC.1395.70 Board Name: Ethics committee of Royan infertility institute Board Affiliation: Reza Samani Phone: [phone] Email: [e-mail]

Yes Health, Treatment and Medical Education Ministry: Iran

Hormones replace therapy (Artificial) is a method for endometrium preparation and embryo transfer. In this protocol for decrease of spontaneous ovulation, exogenous estrogen began in 2-3 days on follicular phase of the menstrual cycle which continue about 10 to 14 days. In the following luteal phase support by progesterone begins on 14 to 16 days of cycles. The luteal phase is supported with different dose and duration of estradiol (E2) and progesterone (P) until 8-12 week of pregnancy. Studied reported a higher risk of thromboembolism in pregnant women that using exogenous estrogen. Also, excess estrogen might be resulted fetus congenital anomalies, low birth weight and increased susceptibility to breast cancer in female fetuses. On the other hands, it seems placenta in early pregnancy duration synthesize estrogen and this time estrogen sufficient as a product of progesterone metabolism. We aimed to decrease quantity of exogenous estrogen and evaluated the success rate of ongoing pregnancy in women undergone artificial FET who have a surplus embryos at previous fertility treatment cycles.

In this study, endometrial prepared with standard long GnRH protocol and for luteal phase support patients received 6 mg oral E2 and intramuscularly P 100 mg/d and embryos on day 2-3 were transferred. Control group continued E2 until 12 week of pregnancy, while for cases after identify gestational sac with heart beat (the 6 week of pregnancy) by vaginal ultrasonography, E2 will discontinued.

The level of maternal estrogen and progesterone measured at progesterone days (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.

This study is a randomized clinical trial to investigate the duration of estrogen for luteal phase in pregnant women undergone frozen embryo transfer cycles- Randomized controlled trials phase III. The study protocol is approved by the Ethics Committee (Institutional Review Board) of Royan institute and all participants provide informed consent.

Enrollment: 60 patients

Sex: Female

Ages: 21 to 37 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients with surplus embryos undergone infertility treatment cycles (e.g. OHSS, inadequate endometrium, surplus frozen embryo from any cause)
2. Age 21-37 years
3. Normal BMI (18.5 <BMI <30)
4. IVF / ICSI or IVF or ICSI cycles with antagonists or agonists protocols
5. Frozen embryos on 2-3 days

Exclusion criteria

1. Endometrial thickness ≤7mm
2. Egg Donors
3. Surrogacy
4. Male factor infertility with azoospermia
5. Age <37 years old
6. Hydrosalpinx
7. Uterine anomalies
8. Myoma with a compression effect or submocusa myoma
9. PGD
10. Blastocyst embryo transfer, ZIFT and GIFT

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

FET cycle, discontinue estradiol after 6 gestational weeks

Experimental group

Description:

In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.

Treatment:

Drug: Strogen

Drug: Strogen

FET cycle, continue estradiol till 12 gestational weeks

Active Comparator group

Description:

Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.

Treatment:

Drug: Strogen

Drug: Strogen